Champions Oncology, Inc. (CSBR): Price and Financial Metrics


Champions Oncology, Inc. (CSBR): $7.51

-0.07 (-0.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CSBR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CSBR Stock Summary

  • CHAMPIONS ONCOLOGY INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.71% of US listed stocks.
  • With a one year PEG ratio of 194.78, CHAMPIONS ONCOLOGY INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 88.27% of US stocks.
  • CSBR's current price/earnings ratio is 252.91, which is higher than 98.56% of US stocks with positive earnings.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CHAMPIONS ONCOLOGY INC are ICCC, VIAV, PAY, RDWR, and EMAN.
  • CSBR's SEC filings can be seen here. And to visit CHAMPIONS ONCOLOGY INC's official web site, go to www.championsoncology.com.

CSBR Valuation Summary

  • CSBR's price/sales ratio is 2.1; this is 10.53% higher than that of the median Healthcare stock.
  • Over the past 190 months, CSBR's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for CSBR.

Stock Date P/S P/B P/E EV/EBIT
CSBR 2022-09-23 2.1 11.9 266.3 246.0
CSBR 2022-09-22 2.2 12.4 277.6 256.3
CSBR 2022-09-21 2.3 13.2 295.8 272.9
CSBR 2022-09-20 2.4 13.7 306.2 282.5
CSBR 2022-09-19 2.4 13.7 307.5 283.6
CSBR 2022-09-16 2.3 13.5 302.2 278.8

CSBR Growth Metrics

    The 2 year price growth rate now stands at 1.05%.
  • Its 5 year revenue growth rate is now at 137.67%.
  • Its 5 year cash and equivalents growth rate is now at 86.29%.
CSBR's revenue has moved up $23,090,000 over the prior 33 months.

The table below shows CSBR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 51.601 6.086 0.401
2022-03-31 49.109 6.497 0.548
2021-12-31 46.796 3.721 0.438
2021-09-30 44.415 -0.401 0.391
2021-06-30 42.746 -0.75 0.115
2021-03-31 41.04 -1.681 0.362

CSBR Price Target

For more insight on analysts targets of CSBR, see our CSBR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.67 Average Broker Recommendation 1.5 (Moderate Buy)

CSBR Stock Price Chart Interactive Chart >

Price chart for CSBR

CSBR Price/Volume Stats

Current price $7.51 52-week high $10.38
Prev. close $7.58 52-week low $6.81
Day low $7.38 Volume 6,600
Day high $7.58 Avg. volume 7,153
50-day MA $8.39 Dividend yield N/A
200-day MA $8.01 Market Cap 101.55M

Champions Oncology, Inc. (CSBR) Company Bio


Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.


CSBR Latest News Stream


Event/Time News Detail
Loading, please wait...

CSBR Latest Social Stream


Loading social stream, please wait...

View Full CSBR Social Stream

Latest CSBR News From Around the Web

Below are the latest news stories about CHAMPIONS ONCOLOGY INC that investors may wish to consider to help them evaluate CSBR as an investment opportunity.

Champions Oncology Reports Record Quarterly Revenue of $13.7 Million

Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2023, ended July 31, 2022.

Yahoo | September 8, 2022

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT).

Yahoo | September 6, 2022

What Type Of Shareholders Make Up Champions Oncology, Inc.'s (NASDAQ:CSBR) Share Registry?

If you want to know who really controls Champions Oncology, Inc. ( NASDAQ:CSBR ), then you'll have to look at the...

Yahoo | August 15, 2022

We Ran A Stock Scan For Earnings Growth And Champions Oncology (NASDAQ:CSBR) Passed With Ease

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Yahoo | July 23, 2022

Champions Oncology Reports Quarterly Revenue of $12.9 Million

Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2022.

Yahoo | July 21, 2022

Read More 'CSBR' Stories Here

CSBR Price Returns

1-mo N/A
3-mo -3.96%
6-mo -7.28%
1-year -24.98%
3-year 27.50%
5-year 115.80%
YTD -10.17%
2021 -22.52%
2020 29.53%
2019 6.66%
2018 101.29%
2017 53.36%

Continue Researching CSBR

Want to see what other sources are saying about Champions Oncology Inc's financials and stock price? Try the links below:

Champions Oncology Inc (CSBR) Stock Price | Nasdaq
Champions Oncology Inc (CSBR) Stock Quote, History and News - Yahoo Finance
Champions Oncology Inc (CSBR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6288 seconds.